- Raised $28.5M Series B led by OrbiMed, May 2021
- Raised $13M Series D led by Cystic Fibrosis Foundation, Jun 2026
- Raised $1M Seed round, Nov 2018
About
SpliSense is an Israeli clinical-stage biotechnology company focused on developing transformative RNA-based treatments for unmet needs relating to cystic fibrosis (CF) and other genetic pulmonary illnesses. The company's pioneering platform harnesses Antisense Oligonucleotides (ASOs) to target the root cause of diseases by overcoming specific genetic mutations and modulating protein expression and function. Their technology is based on the research of Prof. Batsheva Kerem from the Hebrew University. SpliSense's pipeline includes innovative therapies in various stages, from discovery to clinical phase, with a lead inhaled ASO therapy, SPL84, for cystic fibrosis. The company has robust, diverse IP protecting its technologies and programs. SpliSense utilizes IP-protected algorithms to support the design and optimization of ASOs for efficiency and safety, including reducing the potential of off-target and immunogenic effects. SpliSense's inhaled ASOs are delivered locally and non-invasively to the lungs with minimal systemic exposure.
Funding history · 5 rounds · $42.9M total
Offices
Q&A
- What is SpliSense's primary focus?
- SpliSense is a clinical-stage biopharmaceutical company that develops transformative RNA-based treatments for pulmonary diseases, specifically using Antisense Oligonucleotides (ASOs).
- What is SpliSense's lead product candidate and its current development stage?
- SpliSense's lead candidate is SPL84, an inhaled ASO therapy for cystic fibrosis patients with the 3849+10kb C→T mutation. It is currently in Phase 2b clinical trials.
- Which investors participated in SpliSense's Series B funding round?
- In May 2021, SpliSense raised a Series B round with participation from OrbiMed and Cystic Fibrosis Foundation.
- Has SpliSense received any recent grants?
- Yes, SpliSense received a grant of $8,500,000 from the Cystic Fibrosis Foundation in April 2024, and is projected to receive another grant of $13,000,000 from the same foundation in June 2026.
- What was the most recent regulatory designation SpliSense received for SPL84?
- In May 2024, SpliSense received FDA Fast Track Designation for SPL84 for the treatment of cystic fibrosis.
- What was the outcome of SpliSense's Phase 2 study for SPL84?
- In September 2025, SpliSense reported positive results from its Phase 2 study of SPL84 in cystic fibrosis.
- What is the employee count for SpliSense?
- SpliSense has 11-50 employees.
- What is the total amount of funding SpliSense has raised to date?
- SpliSense has raised a total of $43,000,000 USD.
Team · 10
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | splisense.com/ |
|---|---|
| linkedin.com/company/77849119 |
Identifiers & details
| Legal name | SpliSense Ltd. |
|---|---|
| Founded | 2017 |
| Employees (exact) | 13 |
Radar intelligence
Patents
| EPO | 9 |
|---|
Publications (Crossref)
| Works | 3 |
|---|
Web history (Wayback)
| Domain | splisense.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515535730 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-11-10 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 1 — charge (1) |
| Registered address | דרך מן קלמן 1 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | רישום שעבוד |